| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14656566.1.4.603 |
| P8608 | Fatcat ID | release_f4al3eqgofhp3e5nxilukveehy |
| P698 | PubMed publication ID | 11249505 |
| P2093 | author name string | Chamberlain RS | |
| Kaufman H | |||
| P2860 | cites work | Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor | Q24312048 |
| THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS | Q24669941 | ||
| The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues | Q28141489 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study | Q34377925 | ||
| Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients | Q34619348 | ||
| Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | Q34723863 | ||
| Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer | Q36230110 | ||
| Gene inoculation generates immune responses against human immunodeficiency virus type 1 | Q36284135 | ||
| Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes | Q36363449 | ||
| A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes | Q36365851 | ||
| Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity | Q36366130 | ||
| Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. | Q36914404 | ||
| Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes | Q37094888 | ||
| Virological evidence for the success of the smallpox eradication programme | Q40233544 | ||
| Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance | Q40422790 | ||
| Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses | Q40423014 | ||
| MHC: orchestrating the immune response | Q40606568 | ||
| MHC ligands and peptide motifs: first listing | Q40612811 | ||
| Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells | Q40628577 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Vaccine therapy for cancer | Q40949035 | ||
| Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival | Q40992290 | ||
| Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations | Q41056766 | ||
| Epitope selection and development of peptide based vaccines to treat cancer | Q41236192 | ||
| Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors | Q41236213 | ||
| Route of immunization and the therapeutic impact of recombinant anticancer vaccines | Q41374869 | ||
| Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity | Q41646149 | ||
| Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response | Q41744259 | ||
| Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein | Q45298725 | ||
| Tumour prevention and rejection with recombinant vaccinia. | Q45496947 | ||
| Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen | Q45776022 | ||
| A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate | Q45788353 | ||
| Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs | Q45864659 | ||
| Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression | Q45875169 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 603-614 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Innovations and strategies for the development of anticancer vaccines | |
| P478 | volume | 1 |
| Q36177363 | Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity? |
| Q36786512 | Immunology and immunotherapy approaches for prostate cancer. |
| Q24675936 | The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas |
| Q60951067 | Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations |
Search more.